-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article Source: Immediate Medicine News
On December 23, Novartis announced that the US FDA has approved Leqvio (inclisiran), which is currently the first and only one for lowering low-density lipoprotein cholesterol (also known as "bad cholesterol" or LDL-C).
Cardiovascular (CV) disease is the number one killer in the world, killing more lives than all cancers combined, and it causes one death in every three deaths worldwide
Leqvio's approval by the US FDA is based on the results of phase 3 clinical trials ORION-9, ORION-10 and ORION-11.
Leqvio is an injectable prescription drug used as an adjuvant therapy for diet and maximum tolerated dose statin therapy for the treatment of adult patients with clinical atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia , These patients need an additional reduction in LDL-C
As a "first-in-class" siRNA therapy, Leqvio can bind to the mRNA encoding the PCSK9 protein, reduce its level through RNA interference, and prevent the liver from producing PCSK9 protein
Note: The original text has been deleted
Reference source:
[1] FDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA to lower cholesterol and keep it low with two doses a year.
[2] FDA approves add-on therapy to lower cholesterol among certain high-risk adults
.
